Mary E. Taplin, MD
Assistant Professor, Department of Medicine, Harvard Medical School
DF/HCC Program AffiliationProstate Cancer
My research in prostate cancer has centered in two main areas (1) androgen receptor changes in the evolution of hormone refractory prostate cancer and (2) clinical trials of novel hormone therapy and chemotherapy with correlative molecular endpoints. The androgen receptor research has demonstrated that (1) androgen receptor point mutations occur in about 20-30% of hormone refractory metastases (2) androgen receptor mutations result in functional changes (3) the presense androgen receptor mutations correlates with response to second-line hormone therapies. Clinical trials of novel androgen receptor antagoinists such as mifepristone are ongoing. Other clinical trials include the early use of chemotherapy for patients with biochemical failure of prostate cancer and the use of novel agents such as inhibitors of the gene mTOR combined with chemotherapy in prostate cancer.
View All Publications